He has also expressed caution toward certain interventions, including weight-loss medications like Ozempic, due to potential side effects that could impact his health and career
The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events in 17,604 adults with preexisting cardiovascular disease, overweight or obesity, without diabetes [1] [2]
Through activation of receptors such as FFAR2 and FFAR3, SCFAs directly influence GLP-1 secretion and insulin sensitivity
In 2025 and 2026, regulators shifted focus from mere supply availability to quality control
Trulicity (dulaglutide) is a prescription GLP-1 receptor agonist manufactured by Eli Lilly and approved to help manage type 2 diabetes
GIP showed a diminished effect in boosting insulin secretion in T2D patients, for reasons that are still not understood